## TB Infection Testing Options, TB Infection Testing Nuances

#### **DE TB Update**

Ed Zuroweste MD TB Medical Consultant PA Department of Health Founding Medical Director Migrant Clinicians Network

# Disclosure and Disclaimer

#### Faculty: Ed Zuroweste, MD

**Disclosure**: I have no real or perceived vested interests that relate to this presentation nor do we have any relationships with pharmaceutical companies, biomedical device manufacturers, and/or other corporations whose products or services are related to pertinent therapeutic areas.



1

# TB infection testing interpretation, PPD, TST, Mantoux test (created in 1907)

- Intradermal injection of tuberculin material
- Stimulates a delayed-type hypersensitivity response mediated by T lymphocytes
- In patients with prior mycobacterial exposure, causes induration at the injection site within 48 to 72 hours



3

## TB infection testing interpretation, PPD, TST, Mantoux test

• Interpretation depends on the risk for TB infection and the risk for progression to active TB disease

<u>&gt;</u> 5mm	HIV + (any CD4 count)	Close contact of active contagious case	Abnormal chest radiograph with fibrotic changes consistent with old TB	Immunosuppressed patients: -TNF-alpha inhibitors -chemotherapy -organ transplantation -glucocorticoid treatment (equivalent of $\geq$ 15 mg/day prednisone for $\geq$ 1 month)
<u>≥</u> 10mm	Certain conditions that increase the risk of reactivation -HD -Silicosis -Certain malignancies -DM -Malnutrition -Jejunal bypass -IVDU	Residents and employees in high-risk settings -Prisons -Jails -Healthcare facilities - Mycobacteriology labs -Homeless shelters	Children < 4 yrs age	Foreign born from countries with high incidence TB, in particular those immigrated in past 5 years
<u>&gt;</u> 15mm	Healthy individuals age 4 years and older with low likelihood of true TB infection			

















LabCorp	PATIENT INFORMAT	ION	REPORT STATUS: FINAL	
SPECIMEN INFORMATION			ORDERING PHYSICIAN	
				5-6-C (1
A PROVIDE A CONTRACT OF A CONT	GENDER: Male		3	
	FASTING: Yes		CLIENT INFORMATION	
Lab ref no:	FASTING: IES		Classification (	
OUT FORED. OD /19 /2022 OZ. FINN TOGAT			CARGE MERINE MARKET CONTRACTOR	
COLLECTED: 02/18/2022 07:51AM LOCAL RECEIVED: 02/18/2022	Clinical Info:			
REPORTED: 02/18/2022 04:07PM ET			Clein Rouse and R.L. Societ	
	sa s			
Test Name	Result	Flag	<b>Reference</b> Range	1
QuantiFERON®-TB Gold Plus				
QuantiFERON Incubation	Incubation performed.	NORMAL		
QuantiFERON-TB Gold Plus	Positive	ABNORMAL	Negative	1.51
Chemiluminescence immunoassay	methodology			
QuantiFERON-TB Gold Plus				
QuantiFERON Criteria	Comment	NORMAL		
The QuantiFERON-TB Gold Plus	result is determin	ed by subtractin	ng	
the Nil value from either TB	antigen (Ag) tube.	The mitogen tul	be	
serves as a control for the t	est.	11 1		
QuantiFERON TB1 Ag Value	1.77	NORMAL	IU/mL	
QuantiFERON TB2 Ag Value	1.79	NORMAL	IU/mL	
QuantiFERON Nil Value	0.08	NORMAL	IU/mL	
QuantiFERON Mitogen Value	>10.00	NORMAL	IU/mL	
	na na sana kao mandri na na sana kao mandri na manana sa	untrantenen anderen and		
Performing Laboratory Informatic	m:			
01: Labcorp Dublin, 6370 Wilcox	Poad Dublin ON	130163269 phone	- 800-282-7200 Director	. Dhi
Vincent Ricchiuti	nous, Dublin On, 4	sororeos, phone	. 500 202-7500, Difector	. F111
	그렇게 같이 있는 것 같은 것 같이 가지?	이 아파 아파 아파 아파 아파		

esults				22] (Older 693690631)
b Collection Inform	nation			·····
Specimen ID:		Specimen: Specimen:	Blood Blood, Venous Venipuncture	
Collection Date and Tim Collected By: Received:	e: 2/3/2022 4:06 PM 2/3/2022 4:06 PM			
QUANTIFERON	TB GOLD PLUS			Order:
Status: Final result Visi QUANTIFERON-TB P	ble to patient: Yes (not se Ref Range & PLUS,1T NEGATIVE		None Dx: Sacroil 5 d ago POSITIVE !	liitis (HCC)
QUANTIFERON-TB P Comment: In he of M. tubercu active tubercu QFT result sh of M. tubercu either the in:	Ref Range & PLUS, IT NEGATIVE althy persons who h losis infection and ulosis if infected, ould not be taken a losis infection. Re itial test or a dif	Units ave a low 1: l of progress a single po s reliable o peat testing ferent test	5 d ago POSITIVE ? ikelihood both sion to ositive evidence g, with	
QUANTIFERON-TB P Comment: In he of M. tubercu active tubercu QFT result sh of M. tubercu either the in:	Ref Range & PLUS,1T NEGATIVE althy persons who h losis infection and ulosis if infected, ould not be taken a losis infection. Ref	Units ave a low 1: l of progress a single po s reliable o peat testing ferent test	5 d ago POSITIVE ? ikelihood both sion to ositive evidence g, with	
QUANTIFERON-TB P Comment: In he of M. tubercu active tubercu QFT result sh of M. tubercu either the in considered on	Ref Range & PLUS, IT NEGATIVE althy persons who h losis infection and ulosis if infected, ould not be taken a losis infection. Re itial test or a dif a case-by-case bas	Units ave a low 1: l of progress a single po s reliable o peat testing ferent test	5 d ago POSITIVE ? ikelihood both sion to ositive evidence g, with , may be	
QUANTIFERON-TB P Comment: In he of M. tubercu active tubercu QFT result sh of M. tubercu either the in considered on NIL	Ref Range & PLUS, IT NEGATIVE althy persons who h losis infection and ulosis if infected, ould not be taken a losis infection. Re itial test or a dif a case-by-case bas IU/mL	Units ave a low 1: l of progress a single po s reliable o peat testing ferent test	5 d ago POSITIVE ! ikelihood both sion to ositive evidence g, with , may be 0.06	

			OV
PLUS, 1 TUBE		POSITIVE NEGATIVE	~~ ~
		In healthy persons who have a low	
		likelihood both of M. tuberculosis	
		infection and of progression to	
		active tuberculosis if infected, a	
		single positive QFT result should not	
	1	be taken as reliable evidence of M.	
		tuberculosis infection. Repeat	
		testing, with either the initial test	
	*	or a different test, may be	
		considered on a case-by-case basis.	
NIL MITOGEN-NIL	0.04	IU/mL	
TB1-NIL	>10.00	IU/mL	
TB2-NIL	0.47	IU/mL	
TDS-NTD	0.27	IU/mL	
The Nil tube value re:	flects the backgrou	nd interferon	
damma immuna regnonge	of the patient's h	lood sample.	
Semmer Tunnente Tesponse		The second se	
This value has been so	ubtracted from the	patient's	
This value has been su displayed TB and Mito	ubtracted from the	patient's	
This value has been so displayed TB and Mitog	ubtracted from the gen results.	41	
This value has been so displayed TB and Mitog Lower than expected re	ubtracted from the gen results. esults with the Mit	ogen tube	
This value has been so displayed TB and Mito Lower than expected re prevent false-negative	ubtracted from the gen results. esults with the Mit e Quantiferon readi	ogen tube	
This value has been so displayed TB and Mitog Lower than expected re	ubtracted from the gen results. esults with the Mit e Quantiferon readi	ogen tube	
This value has been so displayed TB and Mito Lower than expected re prevent false-negative	ubtracted from the gen results. esults with the Mit e Quantiferon readi	ogen tube	
This value has been so displayed TB and Mitog Lower than expected re prevent false-negative detecting a patient w	ubtracted from the gen results. esults with the Mit e Quantiferon readi	ogen tube ngs by nune	E 1 OF 2
This value has been so displayed TB and Mitog Lower than expected re prevent false-negative detecting a patient with LENT SERVICES:	ubtracted from the gen results. esults with the Mit e Quantiferon readi ith a potential imm SPECIMEN	ogen tube ngs by nune	E 1 OF 2

#### TB infection testing interpretation, Quantiferon gold plus **QUANTIFERON TB GOLD** QFT PLUS INTERPRETATION INDETERMINATE Comment: 11/19/15 1021 Collected: An Indeterminate interpretation can be caused by a number of Resulting lab: LABCORP factors, including sample collection. Testing should be Reference range: Negative reordered and a new sample collected on patients with Value: Indeterminate ! indeterminate results. Samples with a low mitogen response Comment: Mitogen (positive control) gave low response. (<0.5) may be due to anergy or immune suppression. Samples This may indicate anergy or immune suppression. Early with a high Nil response (>8.0) may be due to interferon draws and extended transit time may also result in low gamma production independent of TB stimulation or positive control and indeterminate results. heterophile antibodies. For more details, please see TB The specimen received for QuantiFERON testing was incubated Testing Guidance on Staffnet. by the ordering institution. Specific procedures outlined QFT PLUS NIL VALUE 10.000 IU/mL in our Directory of Services and in the package insert for QFT PLUS TB AG1 MINUS 0.000 IU/mL the OuantiFERON Gold (In Tube) test must be followed to NIL enable for proper stimulation of cells for the production QFT PLUS TB AG2 MINUS 0.000 IU/mL of interferon gamma. NIL OFT TB AG VALUE 0.04 OFT PLUS MITOGEN MINUS 0.000 IU/mL QFT NIL VALUE 0.04 NIL QFT MITOGEN VALUE 0.14 OFT TB AG MINUS NIL VALUE 0.00 **QFT INTERPRETATION**

15

#### TB infection testing interpretation, T spot Results are interpreted by subtracting the spot count in the Negative Result Positive Result negative (Nil) control from the Nil Control spot count in Panels A and B Positive: if Panel A minus Nil and/or Panel B minus Nil is > 8 ESAT-6 Panel A spots Negative: if both Panel A minus • Nil and Panel B minus Nil is < 4 CFP10 Panel B spots Equivocal: if the highest of the • Panel A or Panel B spot count is Positive Control such that the (Panel minus Nil) spot count is 5, 6, or 7 spots

#### **TB** infection testing interpretation

- Remember
  - Neither PPD or IGRAs differentiates b/w latent or active TB infection
  - Neither is used to follow response the treatment in a patient with active TB
  - After TB infection both should remain + for life

17



### **TB** infection testing interpretation, Context matters!

- -PPD, + IGRA (not as common)
  - 30 yr old healthy patient from Haiti, PPD 2 yrs ago 0 mm. Now IGRA +
  - 30 yr old patient from Haiti with RA. PPD 2 yrs ago 0 mm. Now IGRA+
  - 30 yr old patient from Haiti with HIV. PPD 2 yrs ago 0 mm. Now IGRA +
  - 18 yr US born patient, healthy, no h/o international travel or known exposures to TB, TB testing done b/c demanded for entry to college, PPD 0mm, quant gold plus Positive in 1 of the tubes at 0.35 IU/ml

19







Ed Zuroweste, MD (814-571-7395) ezuroweste@migrantclinician.org